# PT-141 Benefits Reported in Research | What the Studies Established

> PT-141 benefits reported in research: the RECONNECT desire and distress findings, the central-brain mechanism, and exactly where the approval limits the benefit claim.

What the published PT-141 (bremelanotide) record genuinely establishes — and where the approval ends — read with the effect sizes intact.

## The short version

The clearest **PT-141 benefits** in the research are about desire, in one specific group: premenopausal women with low, distressing sexual desire (HSDD). In two large trials, women on PT-141 reported more desire and less distress about it than women on placebo [3]. The benefit was real and repeatable — and it was modest, not dramatic [3].

The mechanism that produces this benefit is in the brain: PT-141 raises desire-related brain activity for up to a day [5]. That is the established part. Outside that group — in men, in older women, for erections or performance — the evidence is earlier and the use is not approved [1]. This page reads the benefits the way the studies actually measured them, keeps the approved benefit separate from the off-label hopes, and links the contested points to [PT-141 effects](/effects), where the downsides and the criticisms live.

## The established benefit: desire and distress in HSDD

In the two identical Phase 3 RECONNECT trials (n=1267 premenopausal women with HSDD), bremelanotide 1.75 mg as needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks [3]. Both coprimary endpoints were met in both trials [3].

The benefit held up over time. In the 52-week open-label extension (684 women), the desire improvements were sustained and no new safety signals emerged [4]. This is the strongest benefit claim PT-141 supports, and it is the one the FDA approval covers.

## How large is the benefit, honestly

The benefit is statistically significant but small on its scales — an FSFI-desire change near +0.35 and a distress-item change near −0.33 [3]. Independent re-analyses (catalogued on the [PT-141 effects](/effects) page) argue these effects are clinically modest and question the outcome instruments. A regulatory-careful reading reports the number and the criticism side by side: the result is genuine, replicated, and measured — and it is not a large effect. Surfacing the effect size honestly is itself part of describing the benefit accurately.

## PT-141 for women

PT-141 for women is the only context with FDA approval, and only for premenopausal women with acquired, generalized HSDD [10]. The benefit is the desire-and-distress improvement from RECONNECT [3], grounded mechanistically in the human fMRI study showing increased desire and altered sexual brain processing for up to 24 hours [5]. The earliest preclinical signal was in female rats, where PT-141 selectively increased solicitational behavior — the appetitive, wanting side of sexual behavior — without changing reflexive measures [2]. Postmenopausal women are outside the approved population; benefit there is not established.

## PT-141 for men

PT-141 for men is off-label and investigational — not an approved use. The historical interest is real: PT-141 was first developed (including as an intranasal spray) for erectile dysfunction, and an early development profile records a completed Phase IIb ED trial with Phase III planned [8]. The foundational pharmacology in male rats and nonhuman primates showed dose-dependent erectile activity via a central mechanism [1]. But the program that reached approval was the female HSDD program, not an ED indication in men [10]. Any benefit in men remains a research question, not an established or approved outcome — and one 2008 ED salvage study in this area later drew a 2023 Expression of Concern, so the male-ED literature must be read with extra caution [see /effects].

---

A spectrometer-style readout of the PT-141 (bremelanotide) record — every value logged to its source and marked in-spec or contested, the lone 2019 approval for premenopausal HSDD calibrated against every off-label and research-chemical use that sits outside its band; no clinic behind the instrument and nothing here prescribed, dosed, or sold.